1433903-97-9

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 174463-53-7 8-fluoro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 825-22-9 3-fluoroanthranilic acid 

Downstream Products

• 1433903-99-1 (2-amino-5-chloro-3-fluoro-phenyl)-phenyl-methanone 
• 1433904-00-7 6-chloro-8-fluoro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carbonitrile 
• 1433904-01-8 trifluoro-methanesulfonic acid 6-chloro-3-cyano-8-fluoro-4-phenyl-quinolin-2-yl ester 
• 1433904-02-9 6-chloro-8-fluoro-4-phenyl-2-piperidin-1-yl-quinoline-3-carbonitrile 
• 935292-90-3 N-(2-acetyl-6-fluorophenyl)-2,2,2-trifluoroacetamide 
• 124623-26-3 1-(2-amino-3-fluorophenyl)ethanone 
• 935292-91-4 1-(2-amino-3-fluoro-5-iodophenyl)ethanone 
• 1433903-98-0 2-amino-5-chloro-3-fluoro-N-methoxy-N-methyl-benzamide 

Relevant academic research and scientific papers

KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO

Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: (I) wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.

NEW ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.

ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.